[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644068":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":31,"responsibleParty":46,"collaborators":50,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":18,"enrollmentInfo":67,"targetDuration":18,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":79,"whyStopped":18,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Daejeon St. Mary's hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm with administered with Vericiguat","EXPERIMENTAL","Subjects assigned to the experimental arm will initiate vericiguat at a daily dose of 2.5 mg, concurrently with their baseline heart failure therapy including standard of care (loop diuretics, MRAs, and SGLT2i). The dose will be targeted to double every 2 weeks, titrating up to a maximum dose of 10 mg.",[13],"Drug: Vericiguat",{"label":15,"type":16,"description":17,"interventionNames":18},"Arm with standard of care","NO_INTERVENTION","This arm is classified as the standard of care control group, where participants receive baseline heart failure therapies including loop diuretics, MRAs, and SGLT2i. During the study period, if a participant in this arm exhibits no symptomatic improvement or demonstrates clinical worsening despite baseline therapy, the investigator will re-evaluate the doses of the existing standard medications and titrate them up to the maximum recommended doses within a permissible range, or adjust the medication combination to prioritize patient safety. Additionally, in cases of accompanied fluid overload, further pharmacological interventions, including the adjustment of diuretics, may be administered.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Vericiguat","Participants will start vericiguat at 2.5 mg once daily, and the dose will be gradually uptitration every 2 weeks to a target dose of 10 mg once daily, depending on tolerability.",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Principal Investigator","CONTACT","+82-42-220-9943","tworugi@daum.net",[32],{"facility":33,"status":18,"city":34,"state":18,"zip":35,"country":36,"countryCode":18,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Daejeon St.Mary's Hospital","Daejeon","34943","South Korea",{"type":38,"coordinates":39},"Point",[40,41],127.38493,36.34913,{"lat":41,"lon":40},[44],{"name":45,"role":28,"phone":29,"phoneExt":18,"email":30},"Principle Investigator",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Jung Sun Cho","Primary Investigator",[51,53,55],{"name":52,"class":6},"Seoul St. Mary's Hospital",{"name":54,"class":6},"Uijeongbu St. Mary Hospital",{"name":56,"class":6},"Incheon St.Mary's Hospital","100644068","phase-4-efficacy-of-verciguat-in-tr-and-rv-failure-100644068",false,"NCT07668739","Efficacy of Verciguat in TR and RV Failure","Efficacy of Vericiguat in HFrEF Patients With Coexisting Severe Tricuspid Regurgitation and Right Heart Failure; Multicenter Pragmatic Randomized Controlled Trial","VERT-HF","Inclusion Criteria:\n\n1. Age more than 19 years old\n2. right ventricular malfunction confirmed with EKG data or cardiac MRI\n3. chronic heart failure with LVEF\\\u003C45%\n4. Patients Who administrated standard treatment of Heart Failur for over the 4 weeks\n5. NTproBNP \\>1000, NTproBNP \\>1600 with atrial fibrillation or The patient who recently experienced worsening heart failure(Recent hospitalization for worsening heart failure or outpatient administration of intravenous diuretics)\n6. Tricuspid regurgitation of greater than moderate severity was confirmed by echocardiogram\n7. Subject who provided voluntary informed consent to participate in the study\n8. Patients who have not been administered vericiguat within the last 6 months\n\nExclusion Criteria:\n\n1. Patients with a systolic blood pressure (SBP) \\\u003C 100 mmHg\n2. Patients currently treated with other sGC stimulators (including vericiguat) or phosphodiesterase-5 (PDE5) inhibitors\n3. Moderate-to-severe right ventricular (RV) failure requiring surgical intervention\n4. Patients who are currently pregnant or of childbearing potential","ALL","19 Years",{"count":68,"type":69},100,"ESTIMATED","INTERVENTIONAL",[72],"PHASE4","The goal of this clinical trial is to learn if the drug vericiguat works to improve right heart function in patients with worsening heart failure who have reduced left ventricular function. It will also examine the effects of the drug on tricuspid regurgitation (TR) and overall clinical outcomes.\n\nThe main questions it aims to answer are:\n\nDoes vericiguat improve right ventricular (RV) function and reduce tricuspid regurgitation (TR)? Does vericiguat reduce the risk of major adverse cardiovascular events (MACE), such as heart failure hospitalizations and cardiovascular death? Does vericiguat improve participants' exercise capacity, quality of life, and renal function?\n\nResearchers have previously seen the benefits of vericiguat in the large-scale VICTORIA trial for worsening heart failure, and it is hypothesized that improvements in right heart function play a key role. This study aims to confirm these specific benefits.\n\nParticipants will:\n\nTake vericiguat as prescribed during the study period. Undergo echocardiograms at enrollment and at 9 months to assess right heart function.\n\nComplete questionnaires (KCCQ-12) and walking tests (6MWT) to evaluate quality of life and exercise capacity.\n\nProvide blood samples to monitor NTproBNP levels and renal function (creatinine).",[75,76],"HFrEF","Tricuspid Regurgitation (TR)",[75,78,22],"TR","NOT_YET_RECRUITING","2026-06-23",{"date":82,"type":83},"2026-06-25","ACTUAL",{"date":85,"type":69},"2026-07-01",{"date":87,"type":69},"2028-05-31",{"name":5,"class":6},1]